Guided Therapeutics (GTHP) Cash & Equivalents Growth (5y) (2015 - 2025)
Guided Therapeutics (GTHP) Cash & Equivalents Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19.12% |
| Sep 30, 2025 | -31.60% |
| Jun 30, 2025 | -24.68% |
| Mar 31, 2025 | 40.51% |
| Dec 31, 2024 | -15.47% |
| Mar 31, 2024 | 136.61% |
| Sep 30, 2023 | 59.87% |
| Jun 30, 2023 | 101.38% |
| Mar 31, 2023 | 89.09% |
| Dec 31, 2022 | 370.80% |
| Sep 30, 2022 | 105.27% |
| Jun 30, 2022 | 123.49% |
| Mar 31, 2022 | 273.31% |
| Dec 31, 2021 | 114.99% |
| Sep 30, 2021 | 166.83% |
| Jun 30, 2021 | 111.09% |
| Mar 31, 2021 | 86.01% |
| Dec 31, 2020 | 39.06% |
| Sep 30, 2020 | 27.56% |
| Jun 30, 2020 | -17.31% |